Author(s): Fernando Bardella
Disruptive Technologies Lab (DTL), Nuclear and Energy Research Institute (IPEN-CNEN).

This whitepaper examines why diverse thinking is not merely a cultural or organizational preference in artificial intelligence, but a technical and governance requirement for trustworthy AI in global life sciences. Framed through a patient-centered and boardroom-relevant lens, it argues that many of the most consequential failures in AI systems do not arise from model architecture alone, but from representation error, proxy-label bias, dataset shift, hidden stratification, weak transportability, and inadequate lifecycle oversight.

Drawing on NIST AI RMF, WHO guidance, IMDRF Good Machine Learning Practice, and recent FDA-EMA principles for AI in drug development, the paper presents AI as a socio-technical capability whose reliability depends on both technical rigor and institutional judgment. It shows how diverse governance can function as a practical quality-assurance protocol and an AI guardrail by improving problem formulation, strengthening external validity, surfacing subgroup risks earlier, and supporting more defensible deployment decisions across heterogeneous markets and populations.

The paper also proposes six industry-standard controls for AI oversight in life sciences organizations: precise outcome definition, representative data curation, strict separation of training and evaluation datasets, external validation across sites or markets, subgroup-specific performance analysis, and post-deployment monitoring for drift and degradation. These controls are framed not only as technical safeguards, but as mechanisms for strategic de-risking that leadership teams can meaningfully oversee.

Intended for executives, AI practitioners, and governance leaders in biotech and life sciences, this whitepaper positions diversity not as a secondary social metric, but as part of the risk, quality, and trust infrastructure required for responsible AI.